EndoSphere’s inventions provide less invasive, safer and more physiologic treatment for obesity, according to a release from EndoSphere.
The company said obesity is its primary target. EndoSphere develops and commercializes devices such as the SatiSphere duodenal insert.
Read the release on the patient for EndoSphere
Related Articles on Procedures for Obesity:
Top 6 Risk Factors for Weight-Loss Surgery
Allergan Asks FDA to Approve Lap-Band Surgery for Teenagers
Obese Patients at Increased Risk of Surgical Infection After Colectomy
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.